mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)
NCT03288350
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Interventions
DRUG:
mDCF + Avelumab
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre